---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037827"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:55:02.720690+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda Q3 net product sales $38.8M, down 41% YoY; generic Hetlioz hurts; two PDUFA dates in H1 2024

## Summary
- Q3 2023 net product sales $38.8M vs $65.3M YoY; net income $0.1M ($0.00 EPS) vs $3.3M ($0.06) prior year.
- Hetlioz sales fell 58% to $17.5M due to at-risk generic launch; Fanapt sales $21.3M, down 11%.
- FDA accepted sNDAs: Fanapt for bipolar I (PDUFA Apr 2, 2024) and Hetlioz for insomnia (PDUFA Mar 4, 2024).
- Tradipitant NDA for gastroparesis ongoing; Phase III motion sickness study over 20% enrolled.
- Vanda to file Supreme Court petition by Jan 12, 2024 in Hetlioz ANDA litigation vs Teva/Apotex.

## SEC filing metadata
- accession: 0001628280-23-037827
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/0001628280-23-037827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/vnda-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037827
- JSON: https://secwatch.observer/filing/0001628280-23-037827.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037827.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue $38.8 million, net income $0.1 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $38.8 million
  - Net income: $0.1 million
  - Result: reported results
  source text: Total net product sales from HETLIOZ ® and Fanapt ® were $38.8 million in the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/0001628280-23-037827-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.